RNAi specialist Dicerna begins clinical trial; Injectable eye medication launches in U.S.;

> RNAi specialist Dicerna Pharmaceuticals ($DRNA) announced that the first patient has been dosed in the Phase Ib/II clinical trial of its candidate for advanced hepatocellular carcinoma (liver cancer). Release

> pSivida ($PSDV) announced that nationwide shipments of its Iluvien injectable, sustained release micro-insert for the eye condition diabetic macular edema will commence on Feb. 23. The product is licensed to Alimera Sciences. Release

> University of North Carolina spin-off Spyryx Biosciences says it is developing a promising inhaled peptide replacement therapy to help cystic fibrosis patients clear mucus from their lungs. More | More

> The FDA approved the new 0.025 mg/day dosage of the Minivelle estradiol transdermal system for the treatment of postmenopausal osteoporosis. Manufacturer Noven Therapeutics says the medication is the world's smallest estrogen therapy patch. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.